Stocks
Apnimed, Inc.APMD
NASDAQHealthcareBiotechnology$18.90
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing oral therapies for obstructive sleep apnea and other sleep-related respiratory disorders. Its lead candidate, AD109, targets the underlying neurological causes of apnea and is in late-stage trials. Investors track Apnimed for its potential to disrupt the CPAP-dominated sleep apnea treatment market.
52W Range: $16.12-$35.29
Congressional Interest in Apnimed, Inc. (APMD)
No congressional trades have been disclosed for Apnimed, Inc. (APMD) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading APMD?
No congressional trades found for this stock.